MindRank Doses First Patient in Phase III Trial of...
Category : Clinical Trial Update 3 March 2026The GLP-1 race just added another serious contender. MindRank has announced that the first patient h...
Newsletter - All News
Newsletter- All News is a comprehensive section of updated news and current trends, specifically curated to keep clinical trials, including breakthroughs in drug research, regulatory approvals, and advancements in study methodologies. Our news covers key trends in trial designs, patient recruitment strategies, and cutting-edge technologies shaping the future of clinical research
ViiV Healthcare Advances Twice-Yearly HIV Treatmen...
Category : Clinical Trial Update 3 March 2026The future of HIV treatment may require just two doses per year. At CROI 2026 in Denver, ViiV Health...
XellSmart Pharmaceutical Co., Ltd. Secures Fourth...
Category : Clinical Trial Update 3 March 2026XellSmart is expanding deeper into neurodegenerative disease. The company has secured its fourth joi...
Lilly’s Orforglipron Beats Oral Semaglutide in Lan...
Category : Clinical Trial Update 28 February 2026Eli Lilly and Company has released detailed results from ACHIEVE-3, a pivotal Phase 3 study in type...
Vanda’s Imsidolimab Moves Closer to Approval for R...
Category : Clinical Trial Update 28 February 2026Vanda Pharmaceuticals Inc. has reached a key regulatory milestone. The US Food and Drug Administrati...
Latest Newsletter Post
-
XellSmart Pharmaceutical Co., Ltd...
3 March 2026
-
ViiV Healthcare Advances Twice-Year..
3 March 2026
-
MindRank Doses First Patient in Pha..
3 March 2026
-
Vanda’s Imsidolimab Moves Closer to..
28 February 2026
-
Lilly’s Orforglipron Beats Oral Sem..
28 February 2026
Subscribe to Our Newsletter!
C-89, Sector-65 Noida-U.P. 201301 (India)
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Customer Care: 18004190155
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com